Glycorex Transplantation AB (FRA:O33) Total Receivables: €0.74 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:O33 Glycorex Transplantation AB FRA:O33
61 GF Score
Price €0.09
GF Value €0.14
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Glycorex Transplantation AB Total Receivables?

Glycorex Transplantation AB FRA:O33 -31.05% 61 Total Receivables is €0.74 Mil as of Mar. 2026. GuruFocus rates FRA:O33 with a GF Score™ of 61/100 and a GF Value™ of €0.14 (Possible Value Trap). The stock has 5 warning signs investors should review.

Glycorex Transplantation AB's Total Receivables for the quarter that ended in Mar. 2026 was €0.74 Mil.

Glycorex Transplantation AB Total Receivables Related Terms

Glycorex Transplantation AB Total Receivables Historical Data

* Premium members only.

The historical data trend for Glycorex Transplantation AB's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Glycorex Transplantation AB Total Receivables Chart

Glycorex Transplantation AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.43 0.57 0.44 0.53 0.49

Glycorex Transplantation AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.66 0.57 0.78 0.49 0.74
FRA:O33
61GF Score
Glycorex Transplantation AB FRA:O33
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Glycorex Transplantation AB Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of €0.74 Mil mean?
Glycorex Transplantation AB (FRA:O33) has a Total Receivables of €0.74 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Glycorex Transplantation AB and its competitors.
Is Glycorex Transplantation AB's Total Receivables too high?
Glycorex Transplantation AB's current Total Receivables is €0.74 Mil. Overall, Glycorex Transplantation AB has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Glycorex Transplantation AB's Total Receivables compare to VRTX and REGN?
Glycorex Transplantation AB's Total Receivables of €0.74 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Glycorex Transplantation AB and its competitors. Glycorex Transplantation AB's current Total Receivables is €0.74 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Glycorex Transplantation AB stock overvalued right now?
Based on GuruFocus' analysis, Glycorex Transplantation AB (FRA:O33) is currently considered Possible Value Trap. The stock's GF Value™ is €0.14, compared to a current price of €0.09 — trading 36.7% below its estimated fair value. The current Total Receivables is €0.74 Mil. Glycorex Transplantation AB's overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Glycorex Transplantation AB (FRA:O33), the current Total Receivables is €0.74 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Glycorex Transplantation AB (FRA:O33) Overvalued in 2026?

Based on GuruFocus' analysis, Glycorex Transplantation AB stock appears to be undervalued. The current stock price of €0.09 is trading 36.7% below its estimated GF Value™ of €0.14. GuruFocus considers Glycorex Transplantation AB to be Possible Value Trap.

Key valuation signals for FRA:O33:

  • Total Receivables: €0.74 Mil
  • GF Value™: €0.14 vs. price of €0.09 (36.7% below fair value)
  • GF Score™: 61/100 with 5 warning signs

No single metric tells the full story. See the FRA:O33 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Glycorex Transplantation AB Business Description

Other Exchanges GTAB B:Sweden
Address Scheelevagen 27, Lund, SWE, 223 63
Glycorex Transplantation AB is a medical technology company. Its main product Glycosorb ABO is used clinically in six continents to facilitate blood group incompatible transplants, especially in kidney transplants from related living donors, but also in transplantation of liver, heart, lung and stem cells. Glycosorb ABO enables grafts regardless of the blood group of donors and recipients. The product is used in extracorporeal blood treatment, that is, a blood treatment that takes place outside the body in the same way as dialysis. Its segment is research, develop, manufacture, market and sell products in the field of organ transplantation or related areas. Geographically it operates in Europe, Australia, Singapore, India, and Other countries with majority of revenue from Europe.
61GF Score

Get the complete analysis for FRA:O33

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.09
Price
€0.14
GF Value